Vero Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a first-in-class recombinant fusion protein that self-administers as a subcutaneous injection and dual-inhibits BAFF and APRIL, two critical cytokines in B-cell survival and autoantibody production. Atacicept is currently in Phase 3 clinical development for the treatment of IgA nephropathy (IgAN), a leading cause of kidney failure. Vera is also advancing MAU868, a monoclonal antibody designed to neutralize BK virus, which can cause severe complications in kidney transplant recipients.